Ontrezza Trademark Details

Word Mark | Ontrezza |
---|---|
Status | Alive 802 — Request for Extension of Time to File Opposition |
Current Owner
Serial Number | 86944319 |
---|---|
Status Date | Tuesday, September 13, 2016 |
Filing Date | Tuesday, September 13, 2016 |
Attorney | Matthew O. Brady |
Correspondent
MATTHEW O. BRADY
ALLERGAN, INC
2525 DUPONT DRIVE
IRVINE, CA 92612
ALLERGAN, INC
2525 DUPONT DRIVE
IRVINE, CA 92612
Case File Statements
Goods & Services | Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
---|---|
Translation of Words in Mark | The wording "ONTREZZA" has no meaning in a foreign language. |
Classifications
International Class Codes |
005
|
---|---|
U.S. Class Codes | 006, 018, 044, 046, 051, 052 |
Status | 6 — Active |
Status Date | Tuesday, March 22, 2016 |
Primary Code | 005 |
Trademark Timeline
-
Mar 17 2016Trademark application filed with USPTO
-
Mar 21 2016New Application Entered In Tram
-
Mar 22 2016New Application Office Supplied Data Entered In Tram
-
Jun 27 2016Notification of Non-Final Action E-Mailed
-
Jun 27 2016Non-Final Action E-Mailed
-
Jun 27 2016Non-Final Action Written
-
Jun 27 2016Assigned To Examiner
-
Jun 29 2016Approved For Pub - Principal Register
-
Jun 29 2016Examiner's Amendment Entered
-
Jun 29 2016Notification of Examiners Amendment E-Mailed
-
Jun 29 2016Examiners Amendment E-Mailed
-
Jun 29 2016Examiners Amendment -Written
-
Jul 12 2016Assigned To Lie
-
Jul 15 2016Law Office Publication Review Completed
-
Aug 03 2016Notification of Notice of Publication E-Mailed
-
Aug 23 2016Official Gazette Publication Confirmation E-Mailed
-
Aug 23 2016Published For Opposition
-
Sep 13 2016Extension of Time To Oppose Received